Newsletter Subject

AIDS medicine

From

eko.org

Email Address

us@eko.org

Sent On

Sat, Jul 20, 2024 07:14 AM

Email Preheader Text

that could save millions of lives... Gilead Sciences has a new HIV medicine that could save mi

that could save millions of lives...   Gilead Sciences has a new HIV medicine that could save millions of lives. But it's only available in a few wealthy countries for very rich people. Tell Gilead: make HIV medicine accessible and affordable for everyone. [ Sign the petitionÂ]( {NAME}, Gilead Sciences new vaccine can treat and prevent HIV with just two injections each year. But with a price tag of $42,000 USD, millions of people are missing out on life saving treatment. We could help change this. The International AIDS Conference starts on Monday. It's the perfect platform for Gilead to announce it will make its groundbreaking HIV medicine affordable and accessible for everyone worldwide, not just for rich people. Celebrities like Gillian Anderson and Stephen Fry and the Nobel-winning scientist who helped discover HIV have already signed an open letter urging Gilead to share these vaccines with low and middle income countries. The development and distribution of the Covid vaccine showed us companies will do this when there’s enough public pressure. Will you help build momentum before the AIDS Conference and make this too big for Gilead to ignore? [Add your name to the petition: make HIV medicine accessible and affordable for everyone.]( Each year 1 million people test positive for HIV, and more than 600,000 die from AIDS-related illnesses worldwide. But Gilead's injection could change that by treating AND preventing HIV. It would save and change millions of lives, especially those facing stigma, young women fighting for body autonomy, sex workers and LGBTQ+ people. More than 40 million people have died from AIDS-related illnesses. But HIV is a very manageable health condition when people are able to access care and treatment. Gilead received public money from the US Government for previous research and development of a HIV prevention drug called Truvada. And despite Gilead making billions from selling Truvada each year, the public and the US Government don’t get any of that money. The gatekeeping by big, rich companies needs to end now. [Add your name to the petition calling on Gilead to save lives.]( It’s been done before. Last year after sustained public pressure Johnson & Johnson signed a deal to sell its tuberculosis drug, bedaquiline, in most lower and middle income countries, giving millions access to a cheaper life-saving drug. And the Ekō community has a successful track record of pushing big corporations to do the right thing too. When we took action and called on Covid vaccine patent rights to be waived so that more countries could produce their own cheaper and easily accessible treatments it worked. Let’s do it again. [ Sign the petitionÂ]( Thanks for all that you do, Nish, Nick and the team at Ekō More information: [Celebrities join campaigners in call for cheaper version of ‘gamechanger’ HIV drug for poorer countries]( The Guardian 30 May 2024 [Open Letter]( People's Medicines Alliance 27 May 2024 [How an Innovative Deal Will Give Millions Access to Cheaper Tuberculosis Drugs]( Time 20 June 2023     --------------------------------------------------------------- Ekō is a community of people from around the world committed to curbing the growing power of corporations. We want to buy from, work for and invest in companies that respect the environment, treat their workers well and respect democracy. And we’re not afraid to stand up to them when they don’t. Please help keep Ekō strong by chipping in $3 [Chip in $3]( This email was sent to {EMAIL}. | [Unsubscribe](   --------------------------------------------------------------- Follow Us On Social Media [Facebok]( [Instagram]( [Youtube](Eko.Movement) [Twitter]( [TikTok](eko.movement) [Telegram](

Marketing emails from eko.org

View More
Sent On

06/11/2024

Sent On

04/11/2024

Sent On

24/10/2024

Sent On

21/10/2024

Sent On

02/10/2024

Sent On

01/10/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.